matthew76
Banned
- Awards
- 1
Icariin and Erections
Icariin appears to have some properties similar to Viagra. Icariin is a cGMP-specific PDE5 inhibitor that may have potential in treating erectile dysfunction.
Additional Benefits of Icariin
In laboratory studies, icariin appears to have anti-cancer abilities. Icariin also helps protect the liver from toxicity. :clap2:
Icariin Side Effects
Icariin is not known to have any significant side effects, but long term studies are not yet available.
Icariin Research Update
Effects of icariin on intracavernosal pressure and systematic arterial blood pressure of rat
Zhonghua Yi Xue Za Zhi. 2004 Jan;84(2):142-5.
To realize the effect of icariin on erectile function of penis. RESULTS: Icariin, sidenafil and papaverine increased the ICP in a dose-depended manner. Icariin increases ICP.
Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Asian J Androl. 2003 Mar;5(1):15-8.
AIM: To clarify the mechanism of the therapeutic action of icariin on erectile dysfunction (ED). METHODS: PDE5 was isolated from the human platelet and PDE4 from the rat liver tissue. The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated. Papaverine served as the control drug. RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities. The IC(50) of Icariin and papaverine on PDE5 were 0.432 micromol/L and 0.680 micromol/L, respectively and those on PDE4, 73.50 micromol/L and 3.07 micromol/L, respectively. The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively. CONCLUSION: Icariin is a cGMP-specific PDE5 inhibitor that may be developed into an oral effective agent for the treatment of ED.
Experimental studies of icariin on anticancer mechanism
Zhong Yao Cai. 2000 Sep;23(9):554-6.
Icariin is a kind of new biological respone modifier (BRM) and differentiational agent. In order to further elucidate the reversion of malignant phenotypes of tumor cells and the mechanism of its action, highly metastatic human lung cancer cells(PG) were treated with Icariin in vitro. In this study, MTT assay, radioimmune assay, flow cytometry(FCM) and invasion assay were used. The results showed that ICA could influence the distribution of PG cells cycle and reduce S phase. Moreover, Icariin increased the level of cAMP in PG cells, reduced the level of cGMP and increased the cAMP/cGMP ratio. On the other hand, Icariin decreased PG cells adhesive ratio to laminin substrate and decreased the ability of invasion or migration. These data demonstrate that Icariin maybe a kind of effective anticancer drug.
Purification of icariin from the extract of Epimedium segittatum using high-speed counter-current chromatography.
J Chromatogr A. 2002 Jul 12;962(1-2):239-41.
Icariin was purified from the extract of Epimedium segittatum by high-speed counter-current chromatography with a two-phase solvent system composed of n-hexane-n-butanol-methanol-water (1:4:2:6, v/v). We used two multilayer coil planet centrifuges with different capacities. A 300 mg amount of the extract was separated using a semipreparative instrument equipped with a 230-ml capacity column to yield 103 mg of icariin at 86.2% purity. An 8 g amount of the extract was separated with a large preparative instrument equipped with a 2460-ml capacity column to produce 2.45 g of icariin at 85.7% purity. From these fractions over 98% pure icariin was obtained by recrystallization with water.
Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Zhonghua Yi Xue Za Zhi. 2004 Jan;84(2):142-5.
To clarify the mechanism of the therapeutic action of icariin on erectile dysfunction (ED). The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated by the two-step radioisotope procedure. Papaverine served as the control drug. RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities. The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167 times and 4 times, respectively. CONCLUSION: Icariin is a cGMP-specific PDE5 inhibitor that may be developed into an oral effective agent for the treatment of ED.
source: Ray Sahelian, M.D.
Icariin appears to have some properties similar to Viagra. Icariin is a cGMP-specific PDE5 inhibitor that may have potential in treating erectile dysfunction.
Additional Benefits of Icariin
In laboratory studies, icariin appears to have anti-cancer abilities. Icariin also helps protect the liver from toxicity. :clap2:
Icariin Side Effects
Icariin is not known to have any significant side effects, but long term studies are not yet available.
Icariin Research Update
Effects of icariin on intracavernosal pressure and systematic arterial blood pressure of rat
Zhonghua Yi Xue Za Zhi. 2004 Jan;84(2):142-5.
To realize the effect of icariin on erectile function of penis. RESULTS: Icariin, sidenafil and papaverine increased the ICP in a dose-depended manner. Icariin increases ICP.
Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Asian J Androl. 2003 Mar;5(1):15-8.
AIM: To clarify the mechanism of the therapeutic action of icariin on erectile dysfunction (ED). METHODS: PDE5 was isolated from the human platelet and PDE4 from the rat liver tissue. The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated. Papaverine served as the control drug. RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities. The IC(50) of Icariin and papaverine on PDE5 were 0.432 micromol/L and 0.680 micromol/L, respectively and those on PDE4, 73.50 micromol/L and 3.07 micromol/L, respectively. The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively. CONCLUSION: Icariin is a cGMP-specific PDE5 inhibitor that may be developed into an oral effective agent for the treatment of ED.
Experimental studies of icariin on anticancer mechanism
Zhong Yao Cai. 2000 Sep;23(9):554-6.
Icariin is a kind of new biological respone modifier (BRM) and differentiational agent. In order to further elucidate the reversion of malignant phenotypes of tumor cells and the mechanism of its action, highly metastatic human lung cancer cells(PG) were treated with Icariin in vitro. In this study, MTT assay, radioimmune assay, flow cytometry(FCM) and invasion assay were used. The results showed that ICA could influence the distribution of PG cells cycle and reduce S phase. Moreover, Icariin increased the level of cAMP in PG cells, reduced the level of cGMP and increased the cAMP/cGMP ratio. On the other hand, Icariin decreased PG cells adhesive ratio to laminin substrate and decreased the ability of invasion or migration. These data demonstrate that Icariin maybe a kind of effective anticancer drug.
Purification of icariin from the extract of Epimedium segittatum using high-speed counter-current chromatography.
J Chromatogr A. 2002 Jul 12;962(1-2):239-41.
Icariin was purified from the extract of Epimedium segittatum by high-speed counter-current chromatography with a two-phase solvent system composed of n-hexane-n-butanol-methanol-water (1:4:2:6, v/v). We used two multilayer coil planet centrifuges with different capacities. A 300 mg amount of the extract was separated using a semipreparative instrument equipped with a 230-ml capacity column to yield 103 mg of icariin at 86.2% purity. An 8 g amount of the extract was separated with a large preparative instrument equipped with a 2460-ml capacity column to produce 2.45 g of icariin at 85.7% purity. From these fractions over 98% pure icariin was obtained by recrystallization with water.
Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Zhonghua Yi Xue Za Zhi. 2004 Jan;84(2):142-5.
To clarify the mechanism of the therapeutic action of icariin on erectile dysfunction (ED). The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated by the two-step radioisotope procedure. Papaverine served as the control drug. RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities. The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167 times and 4 times, respectively. CONCLUSION: Icariin is a cGMP-specific PDE5 inhibitor that may be developed into an oral effective agent for the treatment of ED.
source: Ray Sahelian, M.D.
